ArticleCancers2023

A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer.

Cheol-Kyu Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.